levoleucovorin and erucic-acid

levoleucovorin has been researched along with erucic-acid* in 1 studies

Other Studies

1 other study(ies) available for levoleucovorin and erucic-acid

ArticleYear
Mixed Oleic Acid-Erucic Acid Liposomes as a Carrier for Anticancer Drugs.
    Current drug delivery, 2020, Volume: 17, Issue:4

    Liposomes are mostly known to be prepared from phospholipids and lipids and have a remarkable capacity to encapsulate both lipophobic and lipophilic molecules. However, there is little research on developing fatty acid liposomes for chemotherapy.. We have successfully prepared mixed fatty acid liposomes from two monounsaturated fatty acids, namely oleic acid and erucic acid, which stabilised by DOPEPEG2000. The Critical Vesicular Concentration (CVC) of liposomes was found to be within 0.09 to 0.21 mmol dm. Encapsulation of various anticancer drugs such as folinic acid, methotrexate, doxorubicin, or irinotecan resulted in Encapsulation Efficiency (%EE) of up to 90%. Using a 3-(4, 5-dimethylthiazol-2- yl)-2,5-diphenyltetrazolium bromide (MTT) assay, the median Inhibitory Concentration (IC. The results suggest that mixed oleic acid-erucic acid liposomes are a potential new approach to further develop as an alternative vehicle of various drugs for cancer treatment.

    Topics: A549 Cells; Antineoplastic Agents; Cell Proliferation; Cell Survival; Doxorubicin; Drug Carriers; Drug Screening Assays, Antitumor; Erucic Acids; Humans; Irinotecan; Leucovorin; Liposomes; Methotrexate; Oleic Acid; Particle Size; Surface Properties

2020